|
|||||
![]() |
|
Consumer products giant Clorox (NYSE:CLX) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 8% year on year to $1.67 billion. Its non-GAAP profit of $1.45 per share was 6.9% below analysts’ consensus estimates.
Is now the time to buy CLX? Find out in our full research report (it’s free).
Clorox’s Q1 results reflected ongoing challenges in consumer demand and heightened competition across core product categories. CEO Linda Rendle explained that while the company had anticipated a tougher consumer environment for much of the quarter, a notable shift occurred in the latter half as U.S. consumer sentiment weakened and shoppers reprioritized spending—resulting in temporary category softness and sales below expectations. Despite these pressures, management highlighted that market share held steady, and Clorox achieved its tenth consecutive quarter of gross margin expansion, which supported continued investment in brand and product innovation.
Looking ahead, management expects external pressures—including tariffs, ongoing retailer inventory adjustments, and macroeconomic uncertainty—to persist. CFO Luc Bellet noted that while the company’s exposure to tariffs is limited, mitigation efforts such as targeted pricing and cost savings are underway. Clorox continues to prioritize margin management and operational efficiency, reiterating its guidance for full-year adjusted earnings per share, and emphasizing that its portfolio of essential brands positions it to navigate ongoing volatility. Rendle remarked, “We are confident in our ability to manage through uncertainty and deliver value to consumers and shareholders.”
Clorox’s leadership addressed the main factors influencing Q1 performance, with particular emphasis on shifting consumer behaviors and operational adjustments. Management discussed both the impact of external events and the company’s responses.
Clorox expects the coming quarters to be shaped by continued consumer caution, retailer inventory management, and the company’s ability to offset external cost pressures through efficiency gains.
Over the next few quarters, the StockStory team will track (1) Clorox’s ability to manage tariff-related cost pressures through pricing and operational changes, (2) normalization of retailer inventory levels and its impact on sales trends, and (3) consumer adoption of new premium product innovations in a value-focused environment. Continued execution on cost savings and ERP integration will also be closely watched as indicators of future margin performance.
Clorox currently trades at a forward P/E ratio of 18.8×. Should you double down or take your chips? Find out in our free research report.
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
May-19 | |
May-19 | |
May-16 | |
May-15 | |
May-15 | |
May-15 | |
May-12 | |
May-10 | |
May-08 | |
May-08 | |
May-07 | |
May-06 | |
May-06 | |
May-06 | |
May-06 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite